Early Experiences of Contact Laser Vaporization of the Prostate using the 980 nm High Power Diode Laser for Benign Prostatic Hyperplasia

Abstract

Early experience of contact laser vaporization in Japan showed efficacy comparable to transurethral resection of the prostate as a surgical procedure for BPH at 24 weeks. Long-term efficacy of the procedure remains uncertain.

GreenLight HPS laser 120 W vs diode laser 300 W vaporization of the prostate for the treatment of benign prostatic hyperplasia in Japanese patients: A prospective, single‐center, randomized clinical trial

“…23 Further studies are required to elucidate the adequate output power conditions that minimize postoperative complications while ensuring adequate functional outcomes in CVP.The present study confirmed there is no significant difference in the main safety profile between HPS-PVP and CVP. These perioperative and postoperative complications reported in the present study are in line with the results of previous studies 2,3,6,9,11,18. A total of six patients (5.1%) failed to recover self-urination throughout the followup period after surgery.…”

“…In addition, HPS‐PVP has been confirmed as being safe in high‐risk patients and those with ongoing oral anticoagulation 10 . On the other hand, although there are only a limited number of clinical studies on diode laser vaporization at 980 nm, CVP has provided comparable functional outcomes to TURP or transurethral vaporization with a bipolar system 6,11 . At present, there are only two published prospective studies comparing the different types of laser vaporization for BPH 12,13 .…”

“…10 On the other hand, although there are only a limited number of clinical studies on diode laser vaporization at 980 nm, CVP has provided comparable functional outcomes to TURP or transurethral vaporization with a bipolar system. 6,11 At present, there are only two published prospective studies comparing the different types of laser vaporization for BPH. 12,13 To the best of our knowledge, the present study is the first RCT to compare the efficacy and safety of for BPH reported that the hemostasis with the diode laser was excellent and better than that with the HPS-PVP, 12,13 the power for hemostasis was estimated to be equivalent with no significant difference in the decrease of the hemoglobin concentration throughout the operation between the two systems.…”

“…This laser offers a simultaneous absorption in water and hemoglobin, resulting in high tissue ablative properties with good hemostasis 5 . A recent study with diode laser (980 nm) using an end‐firing contact fiber showed a comparable efficacy with the conventional TURP 6 …”

“…5 A recent study with diode laser (980 nm) using an end-firing contact fiber showed a comparable efficacy with the conventional TURP. 6 In the present study, the efficacy and safety of contact laser ablation with the 300 W diode laser system (CVP) vs the HPS-PVP with 120 W LBO laser were tested in patients with BPH in a prospective, single-center, randomized clinical trial (RCT). To the best of our knowledge, the present study is the first RCT comparing 120 W HPS-PVP and 300 W CVP in the treatment of Japanese patients with lower urinary tract symptom (LUTS) associated with BPH.…”